Dahlquist, K. J. V., Huggins, M. A., Yousefzadeh, M. J., Soto-Palma, C., Cholensky, S. H., Pierson, M., Smith, D. M., Hamilton, S. E., & Camell, C. D. (2024). PD1 blockade improves survival and CD8+ cytotoxic capacity, without increasing inflammation, during normal microbial experience in old mice. Nature Aging, 4(7), 915–925. https://doi.org/10.1038/s43587-024-00620-4

Wu, L. W., Tao, J. J., McDonnell, D., & Izar, B. (2024). Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition. Melanoma Research, 34(4), 382–385. https://doi.org/10.1097/cmr.0000000000000974

Straube, J., Bukhari, S., Lerrer, S., Winchester, R. J., Gartshteyn, Y., Henick, B. S., Dragovich, M. A., & Mor, A. (2024). PD-1 signaling uncovers a pathogenic subset of T cells in inflammatory arthritis. Arthritis Research & Therapy, 26(1). https://doi.org/10.1186/s13075-023-03259-5

Wang, Y., He, S., Calendo, G., Bui, T., Tian, Y., Lee, C. Y., Zhou, Y., Zhao, X., Abraham, C., Mo, W., Chen, M., Sanders-Braggs, R., Madzo, J., Issa, J.-P., Hexner, E. O., Wiest, D. L., Reshef, R., Xue, H.-H., & Zhang, Y. (2024). Tissue-infiltrating alloreactive T cells require Id3 to deflect PD-1–mediated immune suppression during GVHD. Blood, 143(2), 166–177. https://doi.org/10.1182/blood.2023021126

Gill, A. L., Wang, P. H., Lee, J., Hudson, W. H., Ando, S., Araki, K., Hu, Y., Wieland, A., Im, S., Gavora, A., Medina, C. B., Freeman, G. J., Hashimoto, M., Reiner, S. L., & Ahmed, R. (2023). PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors. Science Immunology, 8(86). https://doi.org/10.1126/sciimmunol.adg0539

Perdigoto, A. L., Deng, S., Du, K. C., Kuchroo, M., Burkhardt, D. B., Tong, A., Israel, G., Robert, M. E., Weisberg, S. P., Kirkiles-Smith, N., Stamatouli, A. M., Kluger, H. M., Quandt, Z., Young, A., Yang, M.-L., Mamula, M. J., Pober, J. S., Anderson, M. S., Krishnaswamy, S., & Herold, K. C. (2022). Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor–induced diabetes. JCI Insight, 7(17). https://doi.org/10.1172/jci.insight.156330

Maniar, A., Haslam, A., & Prasad, V. (2022). Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer, 164, 95–104. https://doi.org/10.1016/j.ejca.2022.01.006